These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22204230)

  • 21. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care.
    McHutchison JG
    Liver Int; 2011 Jan; 31 Suppl 1():29-35. PubMed ID: 21205135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.
    Bitetto D; Fattovich G; Fabris C; Ceriani E; Falleti E; Fornasiere E; Pasino M; Ieluzzi D; Cussigh A; Cmet S; Pirisi M; Toniutto P
    Hepatology; 2011 Apr; 53(4):1118-26. PubMed ID: 21480318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
    Nelson DR
    Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.
    Seto WK; Tanaka Y; Liu K; Lai CL; Yuen MF
    Am J Gastroenterol; 2011 May; 106(5):1007-8. PubMed ID: 21540909
    [No Abstract]   [Full Text] [Related]  

  • 25. Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.
    Gouda HM; El-Saadany ZA; Foad NB; Salama RM
    DNA Cell Biol; 2014 Sep; 33(9):642-6. PubMed ID: 24999753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
    Huang CF; Yeh ML; Huang JF; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wang LY; Hsi E; Juo SH; Dai CY; Chuang WL; Yu ML
    Antiviral Res; 2012 Feb; 93(2):239-244. PubMed ID: 22193282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of interleukin-28B testing in patients with genotype 1.
    Lai M; Afdhal NH
    Hepatology; 2012 Jul; 56(1):367-72. PubMed ID: 22511388
    [No Abstract]   [Full Text] [Related]  

  • 28. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients.
    Tsubota A; Shimada N; Yoshizawa K; Furihata T; Agata R; Yumoto Y; Abe H; Ika M; Namiki Y; Chiba K; Fujise K; Tada N; Aizawa Y
    Liver Int; 2012 May; 32(5):826-36. PubMed ID: 22212648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-nucleotide polymorphisms of IL-10 and IL-28B as predictors of the response of IFN therapy in HCV genotype 4-infected children.
    Shaker OG; Nassar YH; Nour ZA; El Raziky M
    J Pediatr Gastroenterol Nutr; 2013 Aug; 57(2):155-60. PubMed ID: 23880623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus infection and genetic susceptibility to therapy.
    Sibbing B; Nattermann J
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):397-406. PubMed ID: 22187706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
    Wei L; Han T; Yang D; Heo J; Shang J; Cheng J; Chen X; Xie Q; Kim JH; Kalmeijer R; Ouwerkerk-Mahadevan S; Hoeben E; Lenz O; Verbinnen T; Sinha R; Li M; Scott J; Peeters M; Witek J;
    J Gastroenterol Hepatol; 2016 May; 31(5):912-20. PubMed ID: 26777137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
    World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Imazeki F; Yokosuka O; Omata M
    Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
    Takita M; Hagiwara S; Arizumi T; Hayaishi S; Ueda T; Kitai S; Yada N; Inoue T; Minami Y; Chung H; Ueshima K; Sakurai T; Kudo M
    Digestion; 2011; 84 Suppl 1():56-61. PubMed ID: 22156487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Huang JF; Lin JW; Liang CC; Yang SS; Lin CL; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Kao JH; Yu ML
    Sci Rep; 2015 Jul; 5():11710. PubMed ID: 26130141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Boceprevir for chronic HCV genotype 1 infection.
    Hsu CS; Kao JH
    N Engl J Med; 2011 Jul; 365(2):176-7; author reply 177-8. PubMed ID: 21751913
    [No Abstract]   [Full Text] [Related]  

  • 37. Optimal therapy in genotype 1 patients.
    Farnik H; Mihm U; Zeuzem S
    Liver Int; 2009 Jan; 29 Suppl 1():23-30. PubMed ID: 19207963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.
    Tamai H; Mori Y; Shingaki N; Kawashima A; Tsukuda H; Higashi K; Moribata K; Kawaguchi M; Ueda K; Deguchi H; Inoue I; Maekita T; Iguchi M; Kato J; Ichinose M
    Antivir Ther; 2014; 19(1):107-15. PubMed ID: 24162072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.